AU Patent

AU2014370085B2 — Opioid antagonist formulations

Assigned to Purdue Pharma LP · Expires 2017-10-26 · 9y expired

What this patent protects

In certain embodiments, the present invention is directed to a solid controlled- release dosage form comprising a core comprising a core portion of an opioid antagonist and a shell encasing the core and comprising a shell portion of the opioid antagonist, wherein the release prof…

USPTO Abstract

In certain embodiments, the present invention is directed to a solid controlled- release dosage form comprising a core comprising a core portion of an opioid antagonist and a shell encasing the core and comprising a shell portion of the opioid antagonist, wherein the release profile of the core portion of opioid antagonist is different than the release profile of the shell portion of opioid antagonist.

Drugs covered by this patent

Patent Metadata

Patent number
AU2014370085B2
Jurisdiction
AU
Classification
—
Expires
2017-10-26
Drug substance claim
No
Drug product claim
No
Assignee
Purdue Pharma LP
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.